Takeshita Seiichiro, Kanai Takashi, Kawamura Yoichi, Yoshida Yusuke, Nonoyama Shigeaki
Division of Nursing, National Defense Medical College, Tokorozawa, Saitama, Japan.
Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama, Japan.
PLoS One. 2017 May 23;12(5):e0176957. doi: 10.1371/journal.pone.0176957. eCollection 2017.
We recently reported that the combination of the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) is a novel and useful predictor of intravenous immunoglobulin (IVIG)-resistance in Kawasaki disease (KD). In the present study, to evaluate the effectiveness of the new risk score, we compared its predictive validity to that of previously reported risk scores.
The laboratory records of 437 patients with KD before IVIG therapy were retrospectively analyzed, and the IVIG-responsive (n = 344) and IVIG-resistant (n = 93) patients were compared. The validity of the new score (the combination of NLR≥3.83 and PLR≥150) for predicting IVIG resistance in KD was compared to that of the Kobayashi, Egami and Sano risk scores.
The new score and the Kobayashi score displayed high sensitivity (0.72 and 0.70 respectively) and specificity (0.67 and 0.68 respectively), while the Egami and Sano scores showed high specificity (0.71 and 0.81 respectively) but relatively low sensitivity (0.56 and 0.45 respectively). The odds ratios (ORs) for the new score, the Kobayashi score, the Egami score and the Sano score were 5.34 (95% confidence interval [CI] 3.22-8.85), 4.87 (95% CI 2.96-8.01), 3.14 (95% CI 1.96-5.03) and 3.53 (95% CI 2.17-5.77) respectively.
The predictive validity of the combination of NLR≥3.83 and PLR≥150, which is a simple and convenient indicator, was equal to or higher than that of the other risk scores. This suggests that the new score could be a widely available marker for predicting IVIG resistance in KD.
我们最近报道,中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)的联合是川崎病(KD)中静脉注射免疫球蛋白(IVIG)抵抗的一种新型且有用的预测指标。在本研究中,为评估新风险评分的有效性,我们将其预测效度与先前报道的风险评分进行了比较。
回顾性分析437例KD患者静脉注射IVIG治疗前的实验室记录,并比较IVIG反应型(n = 344)和IVIG抵抗型(n = 93)患者。将新评分(NLR≥3.83和PLR≥150的联合)预测KD中IVIG抵抗的效度与小林、江上和佐野风险评分进行比较。
新评分和小林评分显示出高敏感性(分别为0.72和0.70)和特异性(分别为0.67和0.68),而江上和佐野评分显示出高特异性(分别为0.71和0.81)但相对低敏感性(分别为0.56和0.45)。新评分、小林评分、江上评分和佐野评分的比值比(OR)分别为5.34(95%置信区间[CI] 3.22 - 8.85)、4.87(95% CI 2.96 - 8.01)、3.14(95% CI 1.96 - 5.03)和3.53(95% CI 2.17 - 5.77)。
NLR≥3.83和PLR≥150的联合作为一个简单便捷的指标,其预测效度等于或高于其他风险评分。这表明新评分可能是预测KD中IVIG抵抗的一个广泛可用的标志物。